id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-D-0575-0031,FDA,FDA-2013-D-0575,"Guidance for Industry on Expedited Programs for Serious Conditions—
Drugs and Biologics; Availability",Notice,Notice of Availability,2014-05-30T04:00:00Z,2014,5,2014-05-30T04:00:00Z,,2024-11-11T20:53:08Z,2014-12534,1,0,090000648171f1ea
FDA-2013-D-0575-0032,FDA,FDA-2013-D-0575,"Guidance for Industry on Expedited Programs for Serious Conditions—
Drugs and Biologics",Other,Guidance,2014-05-30T04:00:00Z,2014,5,2014-05-30T04:00:00Z,,2021-05-06T12:58:39Z,,0,0,090000648171fab1
FDA-2013-D-0575-0030,FDA,FDA-2013-D-0575,"Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Guidance for Industry on Expedited
Programs for Serious Conditions— Drugs and Biologics",Notice,Notice of Approval,2014-05-01T04:00:00Z,2014,5,2014-05-01T04:00:00Z,,2021-02-18T18:08:39Z,2014-09914,0,0,09000064816da49d